| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CGTX | Stock Option (right to buy) | Other | $0 | +8.34K | +306.55% | $0.00 | 11.1K | Jun 10, 2022 | Common Stock | 8.34K | $1.92 | Direct | F1, F2, F6 |
| transaction | CGTX | Stock Option (right to buy) | Other | $0 | -2.47K | -22.34% | $0.00 | 8.59K | Jun 10, 2022 | Common Stock | 2.47K | $1.92 | Direct | F1, F2, F6 |
| transaction | CGTX | Stock Option (right to buy) | Other | $0 | +2.47K | +215.63% | $0.00 | 3.61K | Jun 10, 2022 | Common Stock | 2.47K | $1.92 | By: BP Directors, LP | F1, F2, F3, F4, F5, F6 |
| Id | Content |
|---|---|
| F1 | Consists of options to purchase 8,335 shares of common stock of the Issuer, par value $0.001 per share ("Shares"), granted in consideration for Dr. Aaron Fletcher's services as a director of the Issuer. |
| F2 | These options vest in full on June 10, 2023. |
| F3 | Bios Equity Partners, LP ("Bios Equity I") is the general partner of BP Directors, LP ("Bios Directors"). Cavu Management, LP ("Cavu Management") and Bios Capital Management, LP ("Bios Management") are the general partners of Bios Equity I. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Leslie W. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Dr. Fletcher, is the general partner of Bios Management. |
| F4 | Pursuant to a preexisting agreement, Dr. Fletcher is deemed to hold the reported options for the benefit of Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported options, and Bios Equity I, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors, Mr. Kreis and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported options through his or its respective indirect interest in Bios Directors. |
| F5 | For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
| F6 | This amendment is being filed solely for the purpose of correcting a scrivener's error in this item. The correct exercise price is "$1.92" as shown herein, and not "$1.98" as was inadvertently entered in the original filing. |